• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰前列腺癌筛查随机研究中前列腺癌的患者教育水平和治疗方式。

Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.

机构信息

Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Finnish Cancer Registry, Helsinki, Finland.

出版信息

Eur J Cancer. 2020 May;130:204-210. doi: 10.1016/j.ejca.2020.02.045. Epub 2020 Mar 28.

DOI:10.1016/j.ejca.2020.02.045
PMID:32229417
Abstract

BACKGROUND

In prostate cancer (PCa), lower education level is associated with less screening, more advanced stage at diagnosis and worse survival. The aim of this study was to estimate the association between education level and treatment modality and subsequently survival.

METHODS

The 9255 men diagnosed with PCa in the Finnish Randomized Study of Screening for Prostate Cancer were included. Cancer stage, comorbidity, education level and primary treatment modality were extracted from the patient records, the Finnish Cancer Registry, Statistics Finland and the National Institute of Health and Welfare, and these covariates were used in logistic regression (treatment selection) and Cox regression (survival analysis).

RESULTS

In high-risk cancers, men with tertiary education were more likely to be treated with radical prostatectomy (odds ratio [OR] = 1.76; 95% confidence interval [CI] = 1.27-2.44) than men with primary education. Men with secondary (OR = 0.57; 95% CI = 0.38-0.84) or tertiary (OR = 0.42; 95% CI = 0.29-0.60) education were managed less frequently with mere hormonal therapy. In locally advanced cases, tertiary education was associated with more curatively aimed therapies and less hormonal therapy (OR for radical prostatectomy = 2.34; 95% CI = 1.49-3.66; OR for radiotherapy = 1.42; 95% CI = 1.09-1.85; OR for hormonal therapy = 0.45; 95% CI = 0.33-0.60). The hazard ratio for PCa death was lower in men with secondary (0.81; 95% CI = 0.69-0.95) and tertiary (0.75; 95% CI = 0.65-0.87) education than in the patients with primary education.

CONCLUSIONS

When controlled for the cancer risk group, comorbidity and patient's age, low education level is independently associated with less curatively aimed treatment in men with high-risk or locally advanced PCa and subsequently worse prognosis.

摘要

背景

在前列腺癌(PCa)中,较低的受教育程度与筛查率较低、诊断时更晚期和生存率较差有关。本研究的目的是评估教育程度与治疗方式之间的关系,并随后评估生存率。

方法

纳入了在芬兰前列腺癌筛查随机研究中诊断为 PCa 的 9255 名男性患者。从患者记录、芬兰癌症登记处、芬兰统计局和国家卫生福利研究所提取癌症分期、合并症、教育程度和主要治疗方式,并将这些协变量用于逻辑回归(治疗选择)和 Cox 回归(生存分析)。

结果

在高危癌症中,接受过高等教育的男性接受根治性前列腺切除术的可能性高于接受过初级教育的男性(优势比[OR] = 1.76;95%置信区间[CI] = 1.27-2.44)。接受过中等教育(OR = 0.57;95%CI = 0.38-0.84)或高等教育(OR = 0.42;95%CI = 0.29-0.60)的男性较少接受单纯激素治疗。在局部晚期病例中,高等教育与更多的根治性治疗和较少的激素治疗相关(根治性前列腺切除术的 OR = 2.34;95%CI = 1.49-3.66;放疗的 OR = 1.42;95%CI = 1.09-1.85;激素治疗的 OR = 0.45;95%CI = 0.33-0.60)。与接受初级教育的患者相比,接受中等教育(0.81;95%CI = 0.69-0.95)和高等教育(0.75;95%CI = 0.65-0.87)的男性患 PCa 死亡的风险比更低。

结论

在控制癌症风险组、合并症和患者年龄后,低教育程度与高危或局部晚期 PCa 男性接受较少的根治性治疗相关,随后预后较差。

相似文献

1
Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.芬兰前列腺癌筛查随机研究中前列腺癌的患者教育水平和治疗方式。
Eur J Cancer. 2020 May;130:204-210. doi: 10.1016/j.ejca.2020.02.045. Epub 2020 Mar 28.
2
Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.前列腺癌患者前列腺切除术后使用他汀类药物与生存 **解析**:原文中,“survival”与“prostatectomy”均与前列腺癌相关,因此译文选择了一个更准确的表达方式,更贴合文本内容。
Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16.
3
Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.他汀类药物的使用与前列腺癌生存:芬兰前列腺癌筛查随机研究。
Eur Urol Focus. 2017 Apr;3(2-3):212-220. doi: 10.1016/j.euf.2016.05.004. Epub 2016 Jun 2.
4
Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.非转移性局部晚期或侵袭性中危前列腺癌患者的 10 年和 15 年前列腺癌特异性死亡率,随机分为单独接受终身内分泌治疗或联合放疗:斯堪的纳维亚前列腺癌研究组 7 号的最终结果。
Eur Urol. 2016 Oct;70(4):684-691. doi: 10.1016/j.eururo.2016.03.021. Epub 2016 Mar 26.
5
Prostate cancer outcomes for men who present with symptoms at diagnosis.诊断时出现症状的男性的前列腺癌预后。
BJU Int. 2017 Jun;119(6):862-871. doi: 10.1111/bju.13622. Epub 2016 Sep 3.
6
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.晚期前列腺癌治疗中早期与延迟雄激素抑制疗法的比较
Cochrane Database Syst Rev. 2002(1):CD003506. doi: 10.1002/14651858.CD003506.
7
Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.在芬兰前列腺癌筛查试验中,最初血清前列腺特异性抗原(PSA)浓度升高的男性中,组织学炎症与随后发生前列腺癌的风险。
BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.
8
The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.芬兰在引入 PSA 检测前后,社会经济地位对前列腺癌特定阶段生存和死亡率的影响。
Int J Cancer. 2018 Mar 1;142(5):891-898. doi: 10.1002/ijc.31109. Epub 2017 Oct 31.
9
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.在筛查间隔期发现的前列腺癌男性的疾病特异性生存:随访 11 年后欧洲前列腺癌筛查随机研究-鹿特丹的结果。
Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.
10
Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.血清胆固醇与前列腺癌风险:芬兰前列腺癌筛查随机研究
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):66-76. doi: 10.1038/s41391-018-0087-0. Epub 2018 Sep 13.

引用本文的文献

1
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.前列腺癌筛查:证据、正在进行的试验、政策及知识空白。
BMJ Oncol. 2023 Apr 20;2(1):e000039. doi: 10.1136/bmjonc-2023-000039. eCollection 2023.
2
Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria.尼日利亚接受高剂量率前列腺近距离放射治疗患者的社会人口统计学和临床病理特征。
Ecancermedicalscience. 2024 Aug 14;18:1740. doi: 10.3332/ecancer.2024.1740. eCollection 2024.
3
Investigating Factors Influencing the National Cancer Screening Program among Older Individuals in Republic of Korea-Data from the Korea National Health and Nutrition Examination Survey VIII.
调查影响韩国老年人国家癌症筛查计划的因素——来自韩国国家健康与营养检查调查VIII的数据
Healthcare (Basel). 2024 Jun 20;12(12):1237. doi: 10.3390/healthcare12121237.
4
No Association of Seropositivity with Advanced Prostate Cancer Risk in the Multiethnic Cohort: A Nested Case-Control Study.多族裔队列研究中血清学阳性与晚期前列腺癌风险无关联:一项巢式病例对照研究。
Cancers (Basel). 2023 Oct 28;15(21):5194. doi: 10.3390/cancers15215194.
5
The Evaluation of Survival Rate in Patients with Prostate Cancer by Bayesian Weibull Parametric Accelerated Failure-Time Model.基于贝叶斯威布尔参数加速失效时间模型的前列腺癌患者生存率评估
Iran J Public Health. 2022 Sep;51(9):2108-2116. doi: 10.18502/ijph.v51i9.10566.
6
Creation and Evaluation of the Illinois Cancer Risk Index as a Predictor of Four Common Cancers.伊利诺伊癌症风险指数的建立与评估:对四种常见癌症的预测作用。
Prev Chronic Dis. 2022 Nov 17;19:E75. doi: 10.5888/pcd19.220104.